Dr Andrew Kompa - Researcher Profile

Biography

Andrew is a Research Fellow with the CCRE in Therapeutics in this Department. Andrew completed his PhD in pharmacology, focusing on beta-adrenergic receptor signaling in cardiovascular disease at The University of Melbourne. His postdoctoral research then led him to Monash University investigating angiotensin and relaxin receptor signaling pathways in cardiac disease.

In 2002, Andrew joined the CCRE in therapeutics with interests in studying the processes involved in cardiac remodeling using in vivo and in vitro models of cardiac disease, with particular interests in developing clinically relevant agents for the treatment of heart failure.

Qualifications

GRAD DIP (DRUG EVAL & PHARM SCI)

Institution: Unversity of Melbourne

Year awarded: 1998

MEDICINE (PHARMACOLOGY)

Institution: Universiy of Melbourne

Year awarded: 1996

HONOURS (PHARMACOLOGY)

Institution: University of Melbourne

Year awarded: 1991

Publications

Journal Articles

See, F., Watanabe, M., Kompa, A.R., Wang, B.H., Boyle, A., Kelly, D.J., Gilbert, R.E., Krum, H., 2013, Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction, Heart Lung and Circulation [P], vol 22, Elsevier Australia, Australia, pp. 122-132.

Zhang, Y., Elsik, M., Edgley, A.J., Cox, A., Kompa, A.R., Wang, B.H., Tan, C.Y., Khong, F.L., Stapleton, D.I., Zammit, S.C., Williams, S.J., Gilbert, R.E., Krum, H., Kelly, D.J., 2012, A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction, International Journal of Cardiology [P], vol e-pub, issue 1, Elsevier Ireland Ltd, Ireland, p. 12.

Liu, S., Wang, B.H., Kompa, A.R., Lekawanvijit, S., Krum, H., 2012, Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate, International Journal of Cardiology [P], vol epub, Elsevier Ireland Ltd, Ireland, pp. 457-458.

Liu, S., Lekawanvijit, S., Kompa, A., Wang, B., Kelly, D., Krum, H., 2012, Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins, Clinical and Experimental Pharmacology and Physiology [E], vol 39, issue 8, Wiley-Blackwell Publishing Asia, Australia, pp. 692-700.

Lekawanvijit, S., Kompa, A.R., Wang, B.H., Kelly, D.J., 2012, Cardiorenal syndrome: the emerging role of protein-bound uremic toxins, Circulation Research [P], vol 111, issue 11, Lippincott Williams & Wilkins, United States, pp. 1470-1483.

Lekawanvijit, S., Kompa, A.R., Manabe, M., Wang, B.H., Langham, R.G., Nishijima, F., Kelly, D.J., Krum, H., 2012, Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate, PLoS ONE [P], vol 7, issue 7 (Art. No: e41281), Public Library of Science, United States, pp. 1-9.

Zhang, Y., Edgley, A.J., Cox, A.J., Powell, A.K., Wang, B.H., Kompa, A.R., Stapleton, D.I., Zammit, S.C., Williams, S.J., Krum, H., Gilbert, R.E., Kelly, D.J., 2012, FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomypathy, European Journal of Heart Failure [P], vol 14, Oxford University Press, Netherlands, pp. 549-562.

Lekawanvijit, S., Kompa, A., Zhang, Y., Wang, B., Kelly, D., Krum, H., 2012, Myocardial infarction impairs renal function, induces renal interstitial fibrosis and increases KIM-1 expression: Implications for the cardiorenal syndrome, American Journal of Physiology - Heart and Circulatory Physiology [E], vol epub, American Physiological Society, United States, pp. 1-11.

Wang, B.H., Reisman, S., Bailey, M., Kompa, A.R., Ayhan, M., Krum, H., Rice, G.E., 2012, Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry, Clinical and translational medicine [E], vol 1, issue Art. No: 11, SpringerOpen, United States, pp. 1-8.

Kompa, A., Wang, B., Xu, G., Zhang, Y., Ho, P., Eisennagel, S., Thalji, R., Marina, J., Kelly, D., Behm, D., Krum, H., 2012, Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction, International Journal of Cardiology [P], vol E, Elsevier Ireland Ltd, Ireland, pp. 1-10.

Dworak, M., Stebbing, M., Kompa, A.R., Rana, I., Krum, H., Badoer, E., 2012, Sustained activation of microglia in the hypothalamic PVN following myocardial infarction, Autonomic Neuroscience: Basic and Clinical [P], vol 169, issue 2, Elsevier BV, Netherlands, pp. 70-76.

Tran, L., Kompa, A., Wang, B., Krum, H., 2011, Evaluation of the effects of Urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, UK, pp. 1-6.

Kompa, A., Wang, B., Phrommintikul, A., Ho, P., Kelly, D., Behm, D., Douglas, S., Krum, H., 2010, Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy, Peptides [P], vol 31, issue 8, Elsevier Inc, United States, pp. 1523-1530.

Tran, L., Kompa, A., Kemp, W., Phrommintikul, A., Wang, B., Krum, H., 2010, Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats, American Journal Of Physiology-Heart And Circulatory Physiology [P], vol 298, issue 2, American Physiological Society, United States, pp. 608-613.

Lekawanvijit, S., Adrahtas, A., Kelly, D., Kompa, A., Wang, B., Krum, H., 2010, Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?, European Heart Journal [P], vol 31, Oxford University Press, UK, pp. 1771-1779.

Martin, J., Connelly, K., Boyle, A., Kompa, A.R., Zhang, Y., Kelly, D.J., Gilbert, R.E., Krum, H., 2010, Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction, International Journal of Cardiology [P], vol 143, Elsevier Ireland Ltd, Ireland, pp. 353-360.

Rana, I., Stebbing, M., Kompa, A., Kelly, D., Krum, H., Badoer, E., 2010, Microglia activation in the hypothalamic PVN following myocardial infarction, Brain Research [P], vol 1326, Elsevier BV, Netherlands, pp. 96-104.

Kemp, W.W., Colman, J., Thompson, K., Madan, A., Vincent, M., Chin-Dusting, J.P., Kompa, A.R., Krum, H., Roberts, S., 2009, Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial, Liver International [P], vol 29, issue 3, Wiley-Blackwell Munksgaard, Denmark, Germany, pp. 427-433.

Kemp, W.W., Kompa, A.R., Phrommintikul, A., Herath, C.B., Jia, Z., Angus, P.W., McLean, C., Roberts, S., Krum, H., 2009, Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats, American Journal Of Physiology-Gastrointestinal And..., vol 297, issue 4, American Physiological Society, United States, pp. 762-767.

Zomer, E., de Ridder, I., Kompa, A.R., Komesaroff, P.A., Gilbert, R.E., Krum, H., 2008, Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension, Clinical and Experimental Pharmacology and Physiology, vol 35, issue 10, Wiley-Blackwell Publishing Asia, Australia, pp. 1147-1150.

Phrommintikul, A., Tran, L., Kompa, A.R., Wang, B.H., Adrahtas, A., Cantwell, D., Kelly, D.J., Krum, H., 2008, Effects of a rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction, American Journal of Physiology: Heart and Circulatory Physiology, vol 294, issue 4, American Physiological Society, United States, pp. 1804-1814.

Kompa, A.R., See, F., Lewis, D., Adrahtas, A., Cantwell, D., Wang, B.H., Krum, H., 2008, Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction, Journal of Pharmacology and Experimental Therapeutics, vol 325, issue 3, American Society for Pharmacology and Experimental Therapeutics, United States, pp. 741-750.

Morritt, A.N., Bortolotto, S.K., Dilley, R.J., Han, X., Kompa, A.R., McCombe, D., Wright, C.E., Itescu, S., Angus, J.A., Morrison, W.A., 2007, Cardiac tissue engineering in an in vivo vascularized chamber, Circulation, vol 115, issue 3, Lippincott Williams & Wilkins, USA, pp. 353-360.

Phrommintikul, A., Cantwell, D., Kompa, A.R., Krum, H., 2006, Effects of specific rho kinase inhibition (GSK 576371) on collagen synthesis in isolated neonatal rat cardiac fibroblasts, European Heart Journal, vol 27, p. 786.

Zomer, E., Kompa, A.R., Komesaroff, P.A., Krum, H., 2006, Urotensin II is a vasoconstrictor in diabetic patients without heart failure or essential hypertension, European Heart Journal, vol 27, p. 532.

Sondermeijer, B., Kompa, A.R., Komesaroff, P.A., Krum, H., 2005, Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension, The American Journal of Hypertension, vol 18, issue 9, Elsevier Inc., USA, pp. 1195-1199.

Cantwell, D., Kompa, A.R., Krum, H., 2005, Effect of rho-kinase inhibition on collagen production in isolated cardiac fibroblasts, European Heart Journal, vol 26, p. 66.

See, F., Kompa, A.R., Martin, J., Lewis, D.A., Krum, H., 2005, Fibrosis as a therapeutic target post-myocardial infarction, Current Pharmaceutical Design, vol 11, issue 4, Bentham Science Publishers Ltd, The Netherlands, pp. 477-487.

Kompa, A.R., Thomas, W.G., See, F., Tzanidis, A., Hannan, R.D., Krum, H., 2004, Cardiovascular role of urotensin II: effect of chronic infusion in the rat, Peptides, vol 25, issue 10, Elsevier Science Inc, USA, pp. 1738-1788.

Kompa, A.R., Thomas, W.G., See, F., Tzanidis, A., Hannan, R.D., Krum, H., 2004, Cardiovascular role of urotensin II: effect of chronic infusion in the rat, Peptides, vol 25, issue 10, Elsevier Inc., United States, pp. 1783-1788.

Lim, M., Honisett, S.Y., Sparkes, C.D., Komesaroff, P.A., Kompa, A.R., Krum, H., 2004, Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure, Circulation, vol 109, issue 10, Lippincott, Williams & Wilkins, USA, pp. 1212-1214.

See, F., Kompa, A.R., Krum, H., 2004, p38 MAP kinase as a therapeutic target in cardiovascular disease, Drug Delivery Today: Therapeutic Strategies, vol 1, issue 2, Elsevier, UK, pp. 149-154.

See, F., Thomas, W., Way, K., Tzanidis, A., Kompa, A.R., Lewis, D., Itescu, S., Krum, H., 2004, p38 Mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat, Journal of the American College of Cardiology, vol 44, issue 8, Elsevier Inc., USA, pp. 1679-1689.

See, F., Thomas, W.G., Way, K., Tzanidis, A., Kompa, A.R., Lewis, D., Itescu, S., Krum, H., 2004, p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat, Journal of the American College of Cardiology, vol 44, issue 8, Elsevier Inc., United States, pp. 1679-1689.

Krum, H., Kompa, A.R., Hannan, R.D., Thomas, W.G., 2003, Emerging role of the urotensin II system in cardiovascular disease, Heart Drug, vol 3, issue 3, S. Karger AG, Switzerland, pp. 153-158.

Kompa, A., Samuel, C.S., Summers, R.J., 2002, Inotropic Responses to Human Gene 2 (B29) Relaxin in a Rat Model of Mocardial infarction (MI): effect of pertussis Toxin, British Journal of Pharmacology, vol 137, Nature Publishing group, London UK, pp. 710-718.

Tan, Y.Y., Dawson, N.F., Kompa, A., Bond, C.P., Claasz, A.A., Wade, J.D., Tregear, G.W., Summers, R.J., 2002, Structural requirements for the interaction of sheep insulin-like factor 3 with relaxin receptors in rat atria, European Journal of Pharmacology, vol 457, issue 2-Mar, Elsevier Science, Amsterdam Netherlands, pp. 153-160.

Kompa, A.R., Summers, R.J., 2000, Lidocaine and surgical modification reduces mortality in a rat model of cardiac failure induced by coronary artery ligation, Journal of Pharmacological and Toxicological Methods, vol 43, Elsevier Science, New York NY USA, pp. 199-203.

Kompa, A.R., Summers, R.J., 1999, Desensitisation and resensitisation of beta1- and putative beta4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure, British Journal of Pharmacology, vol 128, Stockton Press, Basingstoke England, pp. 1399-1406.

Kompa, A.R., Gu, X., Evans, B.A., Summers, R.J., 1999, Desensitisation of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins, Journal of Molecular and Cellular Cardiology, vol 31, Academic Press, London England, pp. 1185-1201.

Conference Proceedings

Kompa, A.R., Summers, R.J., 1999, Desensitisation of inotropic responses to human gene 2 (B29) relaxin in a rat model of congestive heart failure is enhanced by treatment with pertussis toxin, Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Sydney, NSW, Dec 1999, ASCEPT, Sydney NSW Australia, pp. 93-Post 1-41.

Kompa, A.R., Summers, R.J., 1999, Inotropic responses to human gene 2 (B29) relaxin are reduced in a rat model of myocardial infarction (MI), International Society of Heart Research Annual Meeting Australasian section - Engineering Cardiovascular Solutions, Pakatoa Is., Auckland, NZ, Aug 99, Internat. Soc. for Heart Research, Auckland NZ, p. Poster 21.

Kompa, A.R., Summers, R.J., 1998, Comparison of b1 and putative b4- adrenoceptor (AR) mediated responses in a rat model of cardiac failure, Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Hobart, TAS, December 1998, ASCEPT, Sydney NSW Australia, p. 184.

Kompa, A.R., Summers, R.J., 1998, Reduced b-adrenoceptor (b-AR) function in a rat model of myocardial infarctions due to changes in G-protein mRNA, International Society for Heart Research, Sydney, NSW, August 1998, Baker Institute, Prahran Vic Australia, p. 27 P19.

Kompa, A.R., Evans, B.A., Summers, R.J., 1998, Reduced b-adrenoceptor(b-AR)function in a rat model of myocardial infarction(MI) is not associated with changes in expression of receptor phosphorylating enzymes, Proceedings of the Australian Neuroscience Society, Canberra, ACT, Jan 1998, Australian Neuroscience Society, Canberra ACT Australia, p. 145 P102.

Kompa, A.R., Summers, R.J., 1998, The role of G-Proteins in reduced b-adrenoceptor(b-AR function in a rat model of myocardial infarction(MI), Pharmacology and Toxicology, Munchen, Germany, Aug.1998, Munksgaard, Copenhagen, p. 93 A6.

Kompa, A.R., Summers, R.J., 1998, The role of G-proteins in reduced b-adrenoceptors (b-AR) function in a rat model of myocardial infarction (MI), Cardiovascular Function In Health and Disease, Sydney, June 1998, International Society For Autonomic Neuroscience, Sydney NSW Australia, p. Oral 1.

Kompa, A.R., Summers, R.J., 1997, Reduced b adrenoceptor (b- AR) function in a rat model of myocardial infarction (MI) involves changes at the level of G - proteins, Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 30 November - 3 December, 1997, ASCEPT, Syndey, p. 52.

Postgraduate Research Supervisions

Current Supervision

Program of Study:

(DOCTORATE BY RESEARCH).

Thesis Title:

Cardiorenal syndrome: pathophysiology and role of uremic toxins.

Supervisors:

Wang, B (Main), Kompa, A (Associate), Krum, H (Associate).

Completed Supervision

Student:

Tran, L.

Program of Study:

Urotensin II signalling pathway in cardiovascular disease. (PHD) 2011.

Supervisors:

Krum, H (Main), Kompa, A (Associate), Wang, B (Associate).